Robinhood Lists Cannabis Stocks: What MSO Access Means for Investors

For years, buying shares in America's largest cannabis companies meant venturing onto over-the-counter markets, navigating clunky brokerages, or simply giving up. That barrier is falling. Following the federal rescheduling of medical cannabis to Schedule III, Robinhood cannabis stocks are now a reality, with major US multistate operators listed on one of the most popular retail trading platforms in the country. It is a milestone that would have been unthinkable a year ago — and a useful lens for understanding how rescheduling is reshaping the business of weed.

The change is more symbolic than seismic, but symbols matter in a sector that has spent a decade locked out of mainstream finance. Here is what happened, why it became possible, and what investors should — and shouldn't — read into it.

How Cannabis Stocks Reached Robinhood

The catalyst was regulatory. In late April 2026, the DEA rescheduled marijuana from Schedule I to Schedule III, designating it as a substance with accepted medical use and a lower potential for dependence. That reclassification, which currently applies to medical marijuana, did more than change a legal label — it altered the risk calculus for the financial institutions and platforms that had long kept plant-touching cannabis companies at arm's length.

Robinhood responded by adding major US cannabis multistate operators, or MSOs, to its platform. Curaleaf's founder and CEO publicly thanked the Robinhood team for adding the company, framing it as a way to expand access for US investors. Green Thumb Industries — one of the few consistently profitable cannabis operators — was also among the early plant-touching companies added. For retail investors accustomed to Robinhood's frictionless interface, the ability to buy a name like Curaleaf alongside their other holdings represents a genuine shift in accessibility.

Exchange-traded funds were already part of the picture. The AdvisorShares Pure US Cannabis ETF, which trades under the ticker MSOS, has long been available on Robinhood and offers diversified exposure to the sector. As of June 1, 2026, MSOS held roughly $1.03 billion in assets across 118 holdings, with Curaleaf representing its single largest position at about 12.44 percent. The arrival of individual MSO stocks now complements that fund-based access.

Why Rescheduling Opened the Door

The deeper story behind the listings is what Schedule III does to cannabis economics, and the answer runs straight through the tax code. For years, Section 280E of the Internal Revenue Code prohibited cannabis companies from deducting ordinary business expenses like marketing, rent, salaries, and insurance, because they trafficked in a Schedule I substance. The result was punishing effective tax rates that crushed margins even for well-run operators.

With medical product sales no longer subject to 280E under Schedule III, companies can finally deduct standard business expenses. The financial impact has been immediate and visible. Trulieve and Curaleaf, two of the largest cannabis retailers, both turned a profit in the first quarter, with Curaleaf reporting $69.8 million in net income. Their shares have responded accordingly, with both companies seeing their stock rise more than 50 percent over a recent three-month stretch as investors repriced the sector's prospects.

That improved profitability is precisely what makes these stocks more palatable to mainstream platforms and the retail investors who use them. A sector that was structurally unprofitable because of 280E is a hard sell; a sector where the largest players are posting net income and shedding a punitive tax burden is a different proposition entirely. Rescheduling didn't just change a classification — it changed the underlying business model.

What It Means for Retail Investors

For everyday investors, the practical benefit is straightforward: getting exposure to US cannabis companies is now easier than it has ever been. Buying MSO shares through a familiar, low-friction platform like Robinhood should help liquidity and broaden the shareholder base for these companies, drawing in participants who would never have opened a specialty brokerage account to trade over-the-counter cannabis tickers.

It is worth keeping the development in perspective, though. Industry observers have noted that while the listings are a positive signal, they are probably not a game-changer by themselves. Most retail investors who genuinely wanted cannabis exposure already had ways to get it, whether through the MSOS ETF or other channels. The Robinhood listings lower the barrier and improve optics more than they unlock a flood of entirely new capital.

There is also a real risk-management lesson embedded in the recent rally. The market's enthusiasm has been driven heavily by the rescheduling news and its tax implications, and sentiment in cannabis stocks has historically been volatile. The same momentum that pushed leading MSOs up more than 50 percent can reverse quickly if regulatory progress stalls or if the broader move to Schedule III faces legal challenges. Easy access cuts both ways: it makes it simpler to buy in at a peak as well as to invest thoughtfully.

It also helps to understand the difference between buying individual MSO shares and holding a diversified fund like MSOS. Picking a single operator concentrates your exposure on that company's execution, balance sheet, and state-by-state footprint, which can amplify both gains and losses. A fund spreads that risk across dozens of holdings but still rises and falls with the sector's overall fortunes. Neither approach removes the fundamental reality that cannabis remains a young, policy-dependent industry, and the convenience of a tap-to-buy app does not change the underlying volatility of what you are buying.

The Bigger Picture: Cannabis Joins the Mainstream

The Robinhood listings are best understood as one data point in a broader normalization of the cannabis industry within American finance. A sector that was effectively quarantined from conventional capital markets is steadily being integrated, and each step — profitability under a reformed tax code, listings on mainstream platforms, growing institutional attention — reinforces the others.

Much still hangs on what comes next in Washington. The current rescheduling applies to medical marijuana, and a DEA administrative hearing scheduled to begin June 29 will help determine whether all cannabis, including recreational products, should move to Schedule III. The outcome of that process will shape how far the financial normalization can go and whether the recent gains in cannabis equities prove durable or fleeting.

For now, the takeaway is clear. The ability to buy Curaleaf or Green Thumb on Robinhood is not, on its own, a reason to invest — but it is a vivid illustration of how quickly the ground is shifting beneath an industry that spent a decade on the financial fringe. As always, investors should weigh the sector's persistent volatility and regulatory uncertainty against its improving fundamentals, and should consider their own goals and risk tolerance before buying in.

Key Takeaways

• Following April 2026 federal rescheduling to Schedule III, Robinhood now lists major US cannabis MSOs, including Curaleaf and Green Thumb Industries.
• Schedule III lifts the punishing Section 280E tax burden on medical sales, allowing companies to deduct normal business expenses.
• Improved profitability—Curaleaf posted $69.8M in Q1 net income—helped major MSO shares rise more than 50% over a recent three-month span.
• Easier access broadens the investor base and improves liquidity, but analysts call it a positive signal rather than a game-changer.
• A June 29 DEA hearing on extending rescheduling to all cannabis will heavily influence whether the rally holds.

This article is for informational purposes only and is not investment advice. Budpedia is not a licensed financial advisor; consult a qualified professional before making investment decisions.

Explore cannabis news, find dispensaries, and join the community at Budpedia.